Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

Phase 2

Terminated

• Conditions: Asthma
• Interventions: Drug: Fevipiprant

• Registration Number: NCT03650400
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The purpose of this study was to assess the pharmacokinetics (PK) of fevipiprant (QAW039) delivered as a chewable tablet (CT) in pediatric asthma subjects aged 6 to \< 12 years with asthma. The results of this study will support the identification of a fevipiprant dose for subsequent pediatric efficacy studies aiming to provide an exposure similar to that of the to-be marketed adult/adolescent dose. In addition, the first data on safety and tolerability of fevipiprant in this age group was obtained.

Detailed Description

The purpose of this study was to assess the pharmacokinetics (PK) of fevipiprant delivered as a chewable tablet (CT) in pediatric asthma subjects aged 6 to \< 12 years. The results of this study would have supported the identification of a fevipiprant dose for subsequent pediatric efficacy studies aiming to provide an exposure similar to that of the to-be marketed adult/adolescent dose. Based on evaluation of the fevipiprant asthma development program in the recently completed studies (CQAW039A2307/ CQAW039A2314) in the adult population (the analyses of these studies did not meet the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses \[i.e. 150 mg/ 450 mg\]), Novartis decided to discontinue this study (CQAW039B2201).

Study Timeline

• Study First Submitted: 2018-08-27
• Study First Submitted QC: 2018-08-27
• Study First Posted: 2018-08-28
• Study Start: 2019-05-01
• Primary Completion: 2019-12-16
• Study Completion: 2020-01-22
• Results First Submitted: 2020-07-01
• Results First Submitted QC: 2020-07-01
• Results First Posted: 2020-07-20
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-07
• Last Update Posted: 2021-10-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Children
• Written informed consent by parent(s)/legal guardian(s) for the pediatric patient and assent by the pediatric patient (depending on local requirements) must be obtained before any study-specific assessment is performed.
• Confirmed/documented diagnosis of asthma, as defined by national or international asthma guidelines for at least 6 months prior to study enrollment.
• Subjects using asthma rescue medication (e.g. SABA) without asthma controller therapy or patients receiving daily treatment with a stable dose ICS (with or without additional controller such as long-acting β-agonists (LABA), long-acting muscarinic antagonists (LAMA)) for at least 4 weeks prior to Treatment Visit (Day 1).
• Subjects must be able to attend study visits as per Study Visit Assessment Schedule (Section 8) which includes 8 to 9 hours in the clinic/home on the day of End of Treatment Visit and have blood draws as scheduled in the study.

Read More

Exclusion Criteria

• Use of other investigational drugs within 5 half-lives of enrollment, or (within 30 days (for small molecules)/until the expected pharmacodynamic effect has returned to baseline (for biologics)), whichever is longer.
• Subject is unable to ingest banana and/or yogurt
• History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
• History of chronic lung disease other than asthma such as and not limited to, sarcoidosis interstitial lung disease, cystic fibrosis, mycobacterial or other infection (including active tuberculosis or atypical mycobacterial disease).
• History of active bacterial, viral or fungal infection within 6 weeks of Treatment Visit (Day 1).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort A Fevipiprant 75 mg	Fevipiprant	QAW039 75 mg Chewable tablet
Cohort B Feviprant 375 mg	Fevipiprant	QAW039 375 mg Chewable tablet

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics of Fevipiprant by Maximum Plasma Concentration at Steady State (Cmax,ss), After at Least Four Consecutive Days of Dosing	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Maximum plasma concentration (Cmax,ss) steady state following drug administration.
Pharmacokinetics of Fevipiprant by Area Under the Curve From 0 to 24 Hours at Steady State (AUC0-24h,ss), After at Least Four Consecutive Days of Dosing	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Area under the curve (AUC0-24h,ss), steady state following drug administration
Pharmacokinetics of Fevipiprant by Oral Clearance at Steady State (CL/F), After at Least Four Consecutive Days of Dosing	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Oral clearance (CL/F), steady state following drug administration.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of Fevipiprant by CL/F	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.	Pharmacokinetics of fevipiprant by oral clearance (CL/F) at steady state
Pharmacokinetics of Fevipiprant by Tmax,ss	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Pharmacokinetics of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state
Urinary Excretion of Fevipiprant	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.	CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of fevipiprant
Pharmacokinetics of Fevipiprant by Cmin,ss	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Pharmacokinetics of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state
Pharmacokinetics of the Metabolite CCN362 by AUC0-24h,ss	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Pharmacokinetics of CCN362 metabolite of fevipiprant , area under the curve (AUC0-24h,ss) at steady state.
Pharmacokinetics of the Metabolite CCN362 by Cmax,ss	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Pharmacokinetics of CCN362 metabolite of fevipiprant by maximum plasma concentration (Cmax,ss) at steady state
Urinary Excretion of the Metabolite, CCN362	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.	CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of the metabolite, CCN362
Pharmacokinetics of the Metabolite CCN362 by Cmin,ss	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Pharmacokinetics of CCN362 metabolite of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state
Pharmacokinetics of the Metabolite CCN362 by Tmax,ss	End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)	Pharmacokinetics of CCN362 metabolite of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state

Trial Locations

Locations (1)

Novartis Investigative Site; 🇺🇸 San Antonio, Texas, United States